Evolent Health, Inc (NYSE:EVH) Receives Average Recommendation of "Buy" from Brokerages

Key Points

• Evolent Health, Inc. has received an average recommendation of "Buy" from 14 research firms, with one hold and twelve buy ratings, reflecting positive analyst sentiment.
• Piper Sandler increased their price objective for Evolent Health from $16.00 to $18.00, indicating confidence in the company’s growth potential.
• Evolent Health reported a loss of $0.10 EPS for its last quarter, missing analyst expectations, with total revenue down 31.3% year-over-year.

Evolent Health, Inc (NYSE:EVH - Get Free Report) has received an average recommendation of "Buy" from the fourteen research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $18.0714.

A number of analysts recently commented on the company. Piper Sandler increased their price objective on Evolent Health from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Thursday. UBS Group increased their price objective on Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Needham & Company LLC reissued a "buy" rating and issued a $15.00 price target on shares of Evolent Health in a research note on Tuesday, May 13th. Truist Financial raised their price target on Evolent Health from $14.00 to $16.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Finally, JMP Securities reissued a "market outperform" rating and issued a $13.00 price target on shares of Evolent Health in a research note on Friday, June 20th.

Institutional Trading of Evolent Health

A number of hedge funds have recently added to or reduced their stakes in the business. State of Wyoming boosted its stake in Evolent Health by 38.6% in the 2nd quarter. State of Wyoming now owns 45,999 shares of the technology company's stock worth $518,000 after buying an additional 12,812 shares during the last quarter. Hudson Bay Capital Management LP boosted its stake in Evolent Health by 92.2% in the 2nd quarter. Hudson Bay Capital Management LP now owns 760,211 shares of the technology company's stock worth $8,560,000 after buying an additional 364,664 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Evolent Health in the 2nd quarter worth about $58,000. Tower Research Capital LLC TRC boosted its stake in Evolent Health by 313.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 14,202 shares of the technology company's stock worth $160,000 after buying an additional 10,770 shares during the last quarter. Finally, Vident Advisory LLC acquired a new stake in Evolent Health in the 2nd quarter worth about $168,000.

Evolent Health Stock Down 0.1%

EVH opened at $9.63 on Tuesday. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.72. The firm has a market cap of $1.13 billion, a P/E ratio of -5.98 and a beta of 0.73. Evolent Health has a 52 week low of $7.06 and a 52 week high of $32.35. The business's fifty day simple moving average is $10.14 and its 200 day simple moving average is $9.54.

Evolent Health (NYSE:EVH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The technology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.20). The company had revenue of $444.33 million for the quarter, compared to analyst estimates of $459.43 million. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. The firm's revenue was down 31.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.30 EPS. Evolent Health has set its Q3 2025 guidance at EPS. As a group, equities research analysts anticipate that Evolent Health will post 0.08 EPS for the current fiscal year.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.